Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature

This observational, retrospective effort across Europe, US, Australia, and Asia aimed to assess the activity of systemic therapies in EHE, an ultra‐rare sarcoma, marked by WWTR1‐CAMTA1 or YAP1‐TFE3 fusions.

[1]  L. Mariani,et al.  Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A case‐series analysis within the Italian Rare Cancer Network , 2020, Cancer.

[2]  L. V. van de Poll-Franse,et al.  Health-related quality of life and symptom burden of epithelioid hemangioendothelioma patients: a global patient-driven Facebook study in a very rare malignancy , 2020, Acta oncologica.

[3]  Robin L. Jones,et al.  Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial. , 2020, JAMA.

[4]  C. Antonescu,et al.  Variant WWTR1 gene fusions in epithelioid hemangioendothelioma—A genetic subset associated with cardiac involvement , 2020, Genes, chromosomes & cancer.

[5]  J. Hwang,et al.  Treatment and prognosis of hepatic epithelioid hemangioendothelioma based on SEER data analysis from 1973 to 2014. , 2019, Hepatobiliary & pancreatic diseases international : HBPD INT.

[6]  G. Chaudry,et al.  Clinical characterization and long‐term outcomes in pediatric epithelioid hemangioendothelioma , 2019, Pediatric blood & cancer.

[7]  D. Adams,et al.  A Retrospective Review of the Use of Sirolimus for Pediatric Patients With Epithelioid Hemangioendothelioma , 2019, Journal of pediatric hematology/oncology.

[8]  Narasimhan P. Agaram,et al.  Prognostic stratification of clinical and molecular epithelioid hemangioendothelioma subsets , 2019, Modern Pathology.

[9]  O. Basturk,et al.  Complete metabolic response to therapy of hepatic epithelioid hemangioendothelioma evaluated with 18F-fluorodeoxyglucose positron emission tomography/contrast-enhanced computed tomography , 2018, Medicine.

[10]  G. Weinberg,et al.  Epithelioid Hemangioendothelioma as a Model of YAP/TAZ-Driven Cancer: Insights from a Rare Fusion Sarcoma , 2018, Cancers.

[11]  Jun Zhang,et al.  Apatinib for the treatment of pulmonary epithelioid hemangioendothelioma , 2017, Medicine.

[12]  Robin L. Jones,et al.  Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. , 2017, The Lancet. Oncology.

[13]  M. Boerries,et al.  Epithelioid hemangioendotheliomas of the liver and lung in children and adolescents , 2017, Pediatric blood & cancer.

[14]  Robin L. Jones,et al.  Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis , 2017, Acta oncologica.

[15]  J. Blay,et al.  Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Z. Keidar,et al.  Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma—a suitable treatment option: case report and review of anti-angiogenic treatment options , 2015, BMC Cancer.

[17]  J. Blay,et al.  Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma , 2015, Clinical Sarcoma Research.

[18]  J. Blay,et al.  Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. , 2014, The Lancet. Oncology.

[19]  M. Rubin,et al.  Novel YAP1‐TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma , 2013, Genes, chromosomes & cancer.

[20]  J. Blay,et al.  Sorafenib in patients with progressive epithelioid hemangioendothelioma , 2013, Cancer.

[21]  D. Indelicato.  F1000Prime recommendation of Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO). , 2013 .

[22]  Joannie T. Yeh,et al.  Clinical patterns and outcome in epithelioid hemangioendothelioma with or without pulmonary involvement: insights from an internet registry in the study of a rare cancer. , 2011, Chest.

[23]  A. Gabizon,et al.  Malignant epithelioid hemangioendothelioma of the liver successfully treated with pegylated liposomal doxorubicin. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  C. Antonescu,et al.  A novel WWTR1‐CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites , 2011, Genes, chromosomes & cancer.

[25]  C. Antonescu,et al.  Metastatic epitheloid hemangioendothelioma (EHE): Role of systemic therapy and survival. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Fredericks,et al.  Lenalidomide stops progression of multifocal epithelioid hemangioendothelioma including intracranial disease , 2010, Journal of Neuro-Oncology.

[27]  P. Russo,et al.  A case of high-risk penile epithelioid hemangioendothelioma , 2009, Nature Reviews Urology.

[28]  J. Blay,et al.  Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  K. Roszkowski,et al.  Pulmonary epithelioid haemangioendothelioma--interferon 2-alpha treatment--case report. , 2008, Pneumonologia i alergologia polska.

[30]  V. Mazzaferro,et al.  The Place of Liver Transplantation in the Treatment of Hepatic Epitheloid Hemangioendothelioma: Report of the European Liver Transplant Registry , 2007, Annals of surgery.

[31]  M. Kattar,et al.  Spontaneous complete regression of hepatic epithelioid haemangioendothelioma. , 2006, The Lancet. Oncology.

[32]  B. O'Neil,et al.  Response of epithelioid haemangioendothelioma to liposomal doxorubicin. , 2005, The Lancet. Oncology.

[33]  R. Merion,et al.  Epithelioid hemangioendothelioma of the liver disseminated to the peritoneum treated with liver transplantation and interferon alpha-2B. , 2002, Transplantation.

[34]  D. V. van Thiel,et al.  Successful medical treatment of an epithelioid hemangioendothelioma of liver. , 1997, Oncology.

[35]  C. Fisher,et al.  Systemic treatment options for epithelioid haemangioendothelioma: the Royal Marsden Hospital experience. , 2015, Anticancer research.

[36]  M. von Mehren,et al.  An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.